Evidence mapPaperPMID 40467953Full record

ReviewGeroScience2025

Ndufs4

Jackson Nuss, Matt Kaeberlein, Alessandro Bitto, Anthony S Grillo

Abstract readReview
In one paragraph

Review in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jackson NussDepartment of Laboratory Medicine & Pathology, School of Medicine, University of Washington, Seattle, WA, USA.
Matt KaeberleinOptispan, Tukwila, WA, USA.
Alessandro BittoDepartment of Laboratory Medicine & Pathology, School of Medicine, University of Washington, Seattle, WA, USA. ab62@uw.edu.
Anthony S GrilloDepartment of Chemistry, University of Cincinnati, Cincinnati, OH, USA. grilloas@uc.edu.

Funding

PROGRAM ENRICHMENTP30AG013280 · UNIVERSITY OF WASHINGTON · 1995 to 2025
$6.6M
Probing the Influence of Oxygen Toxicity on Tau Hyperphosphorylation caused by Mitochondrial DysfunctionR01AG084718 · UNIVERSITY OF CINCINNATI · 2025 to 2025
$531k
The role of the senescent microenvironment on cancer initiating cells in the colon.U01AG077920 · FRED HUTCHINSON CANCER CENTER · 2025 to 2025
$464k
Activation of C/EBP-β by mitohormesis as a therapy for obesityK01DK128128 · NIDDK · UNIVERSITY OF WASHINGTON · 2023 to 2025
$440k
Metabolic treatment of neurological mitochondrial disordersR21NS136915 · UNIVERSITY OF WASHINGTON · 2025 to 2025
$194k
Probing the Relationship Between Protein Kinase C and mTOR in Mitochondrial FunctionF32NS110109 · NINDS · UNIVERSITY OF WASHINGTON · PI Anthony Steven Grillo · 2021 to 2021
$69k
NIA NIH HHS P30 AG013280NIA NIH HHS R01 AG084718NIA NIH HHS U01 AG077920NIDDK NIH HHS K01 DK128128NINDS NIH HHS F32 NS110109NINDS NIH HHS R01 NS098329NINDS NIH HHS R21 NS136915
6 · The paper itself

Abstract

Mice missing the complex I subunit Ndufs4 of the electron transport chain are widely used as a leading animal model of Leigh syndrome, a pediatric neurodegenerative disorder that leads to premature death. More broadly, this animal model has enabled a better understanding of the pathophysiology of mitochondrial disease and mitochondrial dysfunction in sporadic disorders. Intriguingly, longevity interventions are very effective at treating symptoms of disease in this model. Herein, we introduce the model and its notable features that may help provide insights in longevity research. We performed a retrospective analysis of historical data from our laboratories over the past 10 years regarding the use of this animal model in aging studies, the manifestation and progression of mitochondrial disease, and factors that influence their premature death. We observed a correlation between weight and lifespan in female animals and a sex-independent correlation between the onset of clasping, a typical neurodegenerative symptom, and overall survival. We observed a sexual dimorphism in lifespan with female mice being more resilient despite a similar age of onset of disease symptoms. Lastly, we report increased lifespan and delayed onset of disease symptoms following treatment with 17-alpha-estradiol, a non-feminizing estrogen which can extend lifespan in genetically heterogeneous mice. This analysis serves as a useful guide for researchers utilizing this animal in the discovery of effective interventions for longevity and to prevent the onset of disease. It suggests there may be unprecedented underlying sex-specific differences in patients with Leigh syndrome and further strengthens the connection between normative aging and mitochondrial dysfunction.

Indexed as

Electron Transport Complex ILongevityMitochondrial DiseasesAgingAnimalsDisease Models, AnimalFemaleLeigh DiseaseMaleMiceMice, KnockoutRetrospective StudiesElectron Transport Complex INdufs4 protein, mouseInterventionsLongevityMitochondrial dysfunctionVertebrate models

Identifiers

PMID40467953
PMCPMC12634981

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.